Trial results
$TNGX — vopimetostat and TNG456
Tango Therapeutics, Inc. (TNGX) vopimetostat and TNG456: trial results in NSCLC; glioblastoma and other cancers, 2027.
The catalyst
"The Company now expects to report data from its Phase 1/2 clinical trial of vopimetostat monotherapy in a cohort of patients with NSCLC in January 2027 and data from its Phase 1/2 clinical trial evaluating TNG456 as a monotherapy in NSCLC, glioblastoma, and other cancers in January 2027."
— Tango Therapeutics, Inc., 8-K filed 2026-10-23 · the filing. Checked word for word against the stored document when this page was built; a sentence that did not check out would not be here.
- Event id
TNGX-VOPIMETOSTAT-2026- Company
- Tango Therapeutics, Inc.
- Kind
- Trial results
- Indication
- NSCLC; glioblastoma and other cancers
- Window
- 2027-01-01 – 2027-01-31
- Status
- bar_published
The bar
Published 2026-10-24 11:35 ET, before the event. The text below is the hashed text: paste it into the verify page and your browser will recompute the same digest.
Pass if: Six-month progression-free survival rate in the efficacy-evaluable vopimetostat plus daraxonras… · Objective response rate in the efficacy-evaluable MTAP-deleted, RAS-mutant PDAC population rece…
7 items we could not source — full detail below
EVENT TNGX-VOPIMETOSTAT-2026 SCORED SET evaluable FLOOR floor_daraxonrasib_pfs six_month_pfs_rate >= 90 | Six-month progression-free survival rate in the efficacy-evaluable vopimetostat plus daraxonrasib PDAC population. BAR bar_daraxonrasib_orr objective_response_rate >= 92 | Objective response rate in the efficacy-evaluable MTAP-deleted, RAS-mutant PDAC population receiving vopimetostat plus daraxonrasib.
- SHA-256
02aae02791da8daf9beb0bbd5b4600fc36f09b438fe3c997698ff89e4c512233- Frozen
- yes
- Public post
- https://x.com/i/web/status/2114017998956528109
- OpenTimestamps
- TNGX-VOPIMETOSTAT-2026.txt.ots, submitted 2026-10-25 03:45 ET. A proof that this hash existed by then, anchored in Bitcoin and checkable with the standard
ots verifyclient beside the hashed text, without relying on us or on X. - Wayback Machine
- snapshot of this page, 2026-10-24 11:36 ET
The hashed text above is unchanged and is scored as written. These notes say what we learned about it afterwards.
2026-10-24 12:00 ET — Oct 24, 2026: this bar does not match the event it is sealed to. The event is Tango's January 2027 readout of vopimetostat monotherapy in NSCLC and TNG456 monotherapy (8-K, Oct 23, 2026). Both lines quote the vopimetostat plus daraxonrasib result in MTAP-deleted, RAS-mutant pancreatic cancer (Q2 2026 release): a different regimen, indication and cohort. A monotherapy NSCLC release is not expected to report either number, so this bar cannot score that readout. The bar stays as sealed; this note is the correction.
Criteria as committed
Floor — all must pass
| Id | Field | Test | As written |
|---|---|---|---|
floor_daraxonrasib_pfs |
six_month_pfs_rate |
>= 90 |
Six-month progression-free survival rate in the efficacy-evaluable vopimetostat plus daraxonrasib PDAC population. |
Bar — all must pass
| Id | Field | Test | As written |
|---|---|---|---|
bar_daraxonrasib_orr |
objective_response_rate |
>= 92 |
Objective response rate in the efficacy-evaluable MTAP-deleted, RAS-mutant PDAC population receiving vopimetostat plus daraxonrasib. |
What we could not source before the event
- No CT.gov record, NCT identifier, or single registered trial matching the event; no registered primary outcome measure is available.
- No protocol-defined ITT, mITT, FAS, or PP population; only efficacy-evaluable and safety-evaluable reporting descriptions were found.
- No explicit company success criterion, non-inferiority margin, or statistical alpha.
- No clean, full-sentence pre-event numeric threshold for the zoldonrasib arm.
- No external comparator data; the manual comparator file is a placeholder.
- No options snapshot or market-structure data.
- No sourced numeric safety veto or formal response-confirmation rule.
Verdicts
No verdict has been published for this event yet.